Suven Life Sciences secures 4 product patents for NCE

Suven Life Sciences has secured grant of four product patents, one from Europe, two from New Sri Lanka and one from Korea corresponding to the New Chemical Entities (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2027, 2025 and 2024 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) , Huntingon’s disease, Parkinson and Schizophrenia.

With these patents, Suven has a total of eleven granted patents from Europe, eight granted patents from Sri Lanka, five granted patents from Korea for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease.